Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 19Recruiting 8Terminated 7Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 15Gastrointestinal 7Genitourinary 6Endocrine 6Tumor-Agnostic 4Head & Neck 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2NET 2Thoracic 1Other neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 2Metatropic dwarfism 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 4lanreotide 3Temozolomide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3anlotinib 2Positron Emission Tomography Computed Tomography 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Everolimus 2Etoposide 2Cisplatin 2Capecitabine 2Biopsy 2surufatinib 1sintilimab 1regorafenib 1recombinant interferon alpha 2b-like protein 1pembrolizumab 1gallium Ga 68 dotatate 1copper dotatate CU-64 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1Yttrium-90 1Tomography, Emission-Computed, Single-Photon 1Thalidomide 1Tegafur 1Surgical Procedures, Operative 1Somatostatin 1Rose Bengal B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Everolimus × NET × Clear all
NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

King Faisal Specialist Hospital & Research Center

Phase 1/2 Unknown
30 enrolled
EndocrineNET

Metatropic dwarfism, Neuroendocrine Tumors

NCT01175096 2010-08-04

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Guangdong Provincial People's Hospital

Phase 1/2 Unknown
20 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡